Great post from the swamp. I am not familiar with the author as he only has 9 posts and 7 of them are today.
haoliepastor
Tuesday, 02/20/18 11:20:45 PM
Re: None
0
Post # of 218255
I've been following IPIX since 2009, when it was lowly Cellceutix and .29 and George Eaves was the front man.
Kevetrin intrigued me, but George Eaves did not.
When Eaves left, and Leo came to the fore, I invested in the company.
So, I've been around for a while.
The Dana Farber connection for Phase 1 was fantastic, except the trial took forever due to increasing doses to find the max tolerated.
There was another company I liked at the time named Polymedix.
I didn't put money into it because it was in financial trouble.
Lo and behold, Leo bought it.
My estimation of Leo rose to considerable heights.
The transition of focus to Brilicidin from Kevetrin was a bummer because it was Kevetrin that hooked me.
But the strategy, and continuing strategies since, has only increased my trust in Leo's leadership.
The over all strategy is, and always has been, to show K, B, and P are safe, and that they work, so they can be monetized through partnerships sale or sale of the company.
It was necessary to prove Brilicidin in 3 different indications to maximize its platform potential.
Leo has taken this little bio from nothing to on the verge of being one of the biggest bio success stories.
He hasn't diluted the shareholder and reverse split over and over like many others.
The pump and dump and subsequent short attacks are not on Leo.
He was wise not to try to up list the company because it would have been put in a positon by manipulators to delist or reverse split.
It's been sitting on the OTC where there has been an opportunity to accumulate shares before a partnership is signed which will put it on the Nasdaq and bring in institutions.
Oral dosing for Kevetrin is genius and will greatly increase its effectiveness and market value.
Leo has been building value. Again, Leo has been building value!
Just like he said he would!
haoliepastor
Tuesday, 02/20/18 11:20:45 PM
Re: None
0
Post # of 218255
I've been following IPIX since 2009, when it was lowly Cellceutix and .29 and George Eaves was the front man.
Kevetrin intrigued me, but George Eaves did not.
When Eaves left, and Leo came to the fore, I invested in the company.
So, I've been around for a while.
The Dana Farber connection for Phase 1 was fantastic, except the trial took forever due to increasing doses to find the max tolerated.
There was another company I liked at the time named Polymedix.
I didn't put money into it because it was in financial trouble.
Lo and behold, Leo bought it.
My estimation of Leo rose to considerable heights.
The transition of focus to Brilicidin from Kevetrin was a bummer because it was Kevetrin that hooked me.
But the strategy, and continuing strategies since, has only increased my trust in Leo's leadership.
The over all strategy is, and always has been, to show K, B, and P are safe, and that they work, so they can be monetized through partnerships sale or sale of the company.
It was necessary to prove Brilicidin in 3 different indications to maximize its platform potential.
Leo has taken this little bio from nothing to on the verge of being one of the biggest bio success stories.
He hasn't diluted the shareholder and reverse split over and over like many others.
The pump and dump and subsequent short attacks are not on Leo.
He was wise not to try to up list the company because it would have been put in a positon by manipulators to delist or reverse split.
It's been sitting on the OTC where there has been an opportunity to accumulate shares before a partnership is signed which will put it on the Nasdaq and bring in institutions.
Oral dosing for Kevetrin is genius and will greatly increase its effectiveness and market value.
Leo has been building value. Again, Leo has been building value!
Just like he said he would!
3
